Zokinvy

Active Ingredient(s): Lonafarnib
FDA Approved: * November 20, 2020
Pharm Company: * EIGER BIOPHARMS
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Zokinvy Overview

Lonafarnib, sold under the brand name Zokinvy, is a medication used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in people one year of age and older.[2][3] The most common side effects included nausea vomiting, diarrhea, infection, decreased appetite and fatigue.[2] Lonafarnib was approved for medical use in the United States in November 2020...

Read more Zokinvy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lonafarnib

Recent Zokinvy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lonafarnib
  • Capsule: 50mg, 75mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Lonafarnib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 10 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA